3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Breast
1
Conditions
Breast Neoplasms
10
Carcinoma, Non-Small-Cell Lung
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Neoplasms
4
Breast Diseases
4
Thoracic Neoplasms
3
Respiratory Tract Neoplasms
3
Pancreatic Neoplasms
3
Lung Neoplasms
3
Lung Diseases
3
Leukemia, Myeloid, Acute
3
Bronchial Neoplasms
3
Sezary Syndrome
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Pinealoma
2
Neoplasms, Glandular and Epithelial
2
Neoplasms by Histologic Type
2
Myelodysplastic Syndromes
2
Mycosis Fungoides
2
Lymphoma, T-Cell, Cutaneous
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Mantle-Cell
2
Lymphoma, Large-Cell, Immunoblastic
2
Lymphoma, Large-Cell, Anaplastic
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, Follicular
2
Lymphoma, B-Cell, Marginal Zone
2
Lymphoma
2
Leukemia, Myelomonocytic, Chronic
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Interventions
osimertinib
2
Pemetrexed
2
Carboplatin
2
exemestane
1
entinostat
1
Tyrosine Kinase Inhibitors
1
Erlotinib Hydrochloride
1
Dasatinib
1
Afatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Respiratory Tract Diseases
×
entinostat
×
Clear all
NCT01594398
2021-11-19
ENCORE110
Syndax Pharmaceuticals
Phase 1
Completed
14 enrolled